Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At the end of the day we were green - up almost 14%.Not bad.
6 year old video touting a dead stock.Yeah thats news.
The spread between RGBP/RGBPP has closed to almost .08.I think thats a good sign.
http://www.marketwatch.com/story/regen-biopharma-inc-files-utility-patent-application-on-nr2f6-silenced-car-t-cell-for-solid-tumors-2016-12-15
Company Augments Scope of its NR2F6 Program
SAN DIEGO, December 15, 2016 /PRNewswire via COMTEX/ -- SAN DIEGO, December 15, 2016 /PRNewswire/ --
Regen BioPharma Inc. (otcqb:RGBP), (otcqb:RGBPP) announced today the filing of a [provisional/nonprovisional] utility patent application with the United States Patents and Trademark Office covering NR2F6-silenced CAR T cells. While previous work demonstrated that methodologies developed by Regen and covered under its issued patent #9,091,696 are useful in stimulation of T cell activity, the current patent further modifies T cells to express molecules that act as a localized "danger signal" to the immune system. CAR T cells are T Cells (T lymphocytes) which are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells.
Remarkable clinical results have been obtained by numerous investigators utilizing CAR T cells in the treatment of leukemias and lymphomas [[1]] . Unfortunately, results for solid tumors have been limited [[2]] . This is thought to occur because solid tumors produce numerous immune-suppressive factors that coax the cells that surround the tumor to protect the tumor against the immune response. By utilizing NR2F6-silencing methods, Regen believes it has developed a new method of augmenting the cells that surround the tumor to allow for immune destruction of the tumor to occur.
"When we look at other chronic diseases, it is important to note that effective treatment protocols always involve multifactorial attacks on the disease process. This is best illustrated in the case of HIV where only after the introduction of the "cocktail therapy" approach have significant extensions of lifespan been achieved," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen BioPharma. "By activating the adaptive arm of the immune system, in the form of NR2F6-silenced T cells, we anticipate achieving synergistic effects in killing of solid tumors, something which has not been observed in previous CAR-T approaches."
Augmentation of CAR-T cells has previously been performed with cytokines such as IL-12 [[3]] , however, IL-12 is one signal out of many signals involved in alerting the immune system to "danger". However, by inhibiting NR2F6 in these CAR-T cells, it is very likely that multiple cytokines will secreted leading to an augmented killing effect.
"At Regen BioPharma we are committed to developing the next generation of immune-oncology. By combining silencing of the immune checkpoint NR2F6 with this advanced CAR-T approach, we continue at the cutting edge of intellectual property in this extremely promising and rapidly evolving field," said David Koos, Ph.D., Chairman and Chief Executive Officer of Regen BioPharma.
Glad to see a green close.Good volume.This stock may have a nice Xmas present for us.
Up almost 13% this morning,maybe we can see RGBP/RGBPP return to the 20's by Xmas.
I think things will move along more quickly with the new administration.
Both stocks are trading in the same range with more volume for RGBPP. The new administration is friendly to biopharma stocks and we should see momentum by spring if not sooner.
Thanks PSG !!
Good luck to you Herb
So if you are correct that would make me wonder why you havent moved on ? I have been in plenty of poor performing stocks and I rarely stick with them.The science here has me hooked.This stock will either tank or take us to the promised land.
Agreed.The science convinced me early on.The patents alone are worth alot of money.
At these prices adding more is like an early Xmas present for me.So the longer it takes the cheaper the shares.I scoffed at .05 prediction but now I dont care I am buying at .08 and I will buy at any price under a dime.
The rest of the pipeline should be ready for Phase I trials and our Phase I drug should be cleared for Phase II.On the funding front the outside firm contracted to do that has failed IMO.
The company is not excessively releasing pr's and when they do the price doesnt go up.This is not a stock for the fast buck crowd.
The other number I tried to get was AA Preferred.In past 10Q that number was 600,000.Anyway glad to see that Koos gave the info to the TA.
Perhaps the reason the TA was unable to give me a count of preferred shares Friday may be because the company has given out preferred shares.
The numbers for common shares outstanding that the TA gave me Friday dont support dilution.
The only person at Regen who can talk to the TA is Koos,I got that from Dr Lander and the TA.The breakdown of preferred shares shouldnt be a big deal its reported in the 10Q.Lander said he would have Koos contact me.As its the weekend I guess it will be Monday before I get a response.My advice is to see how this shakes out.I will stay on the issue and will keep everyone informed.
The last 10Q I could fins was July and it had the numbers for both classes of preferred.The TA was probably wanting updated numbers from the company,but it lets the company know that someone is interested.
I also asked the TA to update RGBPP A and AA preferred shares outstanding.He told me to have Koos contact him.Curious dont you think ? I replied as a shareholder that I was entitled to the information.So I will drop Koos an email or Lander.
I emailed Dr Lander with the TA's email to me and asked him to either provide the info or get the TA to comply with my request.
Here is the latest outstanding common shares info per the transfer agent.
The current common issued and outstanding is 139,712,605
I contacted the transfer agent for a share update.
The current common issued and outstanding is 139,712,605
Whats the saying,volume before news ?
Regen in the news today !!
http://tinyurl.com/h7o2ap6
PUNE, India, October 25, 2016 /PRNewswire/ --
Recently published report Global Anemia Drugs Market 2016 - 2021 says rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.
Complete report Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021) spreads across 175 pages, analysing companies based on the type of Anemia and supported with 2 data tables and 38 figures is available at http://www.rnrmarketresearch.com/global-anemia-drugs-market-iron-deficiency-sickle-cell-ckd-aplastic-anemia-analysis-by-region-by-country-2016-2021-by-type-iron-deficiency-anemia-chronic-kidney-disease-related-anemia-sickle-cell-anemi-th-africa-market-report.html.
Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016 - 2021F, on account of rising incidences of anemia globally. North America region remains the major market followed by Europe in the actual period, while APAC and ROW region will witness strong growth in the forecast period.
According to research report, Global Anemia Drugs Market: Trends, Opportunities and Forecasts (2016-2021), Global Anemia Drugs market is projected to exhibit a CAGR of over ~9.05% during 2016 - 2021. On the basis of market segment, Global Anemia Drugs Market has been segmented by Type (Iron Deficiency Anemia, Chronic Kidney Disease related Anemia, Sickle Cell Anemia, Aplastic Anemia); By Region-North America, Europe, APAC, Latin America, MEA; By Country-USA, Canada, UK, Germany, India, Brazil, South Africa). Order a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=731946.
Report's Strategic Recommendations are North America and Europe to Generate High Revenue, Opportunity in Rare Anemia, and Growing Inclination towards Hypoxia inducible factor (HIF) Stabilizers
Company Profiling and Drug Market Potential
Sickle Cell Anaemia: Global Blood Therapeutics (GBT), Bluebird bio, GlycoMimetics and Mast Therapeutics
CKD Anemia: GlaxoSmithKline, Fibrogen, Akebia therapeutics, Bayer AG and Eli Lilly
Aplastic Anemia: Regen biopharma
No they havent dropped Regen,the company is still listed on their web site.Click the link.
Gene silencing has put Benitec in the news.
http://www.fiercebiotech.com/biotech/soon-shiong-swoops-benitec-for-phii-gene-silencing-data
http://www.benitec.com/pipeline/licensed-programs-detail
From the Benitec web site.
5. CANCER VACCINES with Regen Biopharma
Status
In August 2013, Benitec granted a license to US based Regen BioPharma Inc. (Regen), a subsidiary of the Bio-Matrix Scientific Group, to use ddRNAi technology for the development of cancer vaccines.
Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 - dioxygenase (IDO) in dendritic cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents.
The next step is to test Hema out with a group of 20-100 patients that have the disease.
thanks for the reply
The drug works but how do we explain the share price ? Its frustrating to me.
Very promising and I hope the FDA clears RGBP to go forward with Phase II trials.A control group would be necessary I would think.
moving up on low volume nice upswing.
At the low pps we have seen there has been accumulation.If they let it back up to .12 they make .02 a share on a day trade.Not too shabby.
Thanks for bringing the issue up !!
OK I will coordinate the update with the other moderators.
I think we will have news although I was surprised last week when no news was released.The pps was in a down slide last week,so I trust we will see an upturn this week.
Odd trading with RGBPP in the red and RGBP in the green.
The sale price wont be anywhere close to .135 a share.IF there is a sale of the company the day to day price wont matter,I suspect there wont be time to flip.If the price is $5 a share then thats what you get.
Odd the pps of RGBP/RGBPP are about the same.No more premium for the preferred shares.
I think optimism is necessary for this stock as alot of good things are happening.RGBP is definitely not a quick play.I confess to playing that game frequently so staying in one stock over a year is new for me.